SCHEMBL16748486

SCHEMBL16748486

Cc1nc2ccccc2n1-c1nc(NCCO)nc(Nc2ccc3c(c2)OCO3)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 10/20 0.46
PIK3CD O00329 1/20 0.44
PIK3CA P42336 1/20 0.44
PIK3CB P42338 1/20 0.44
PIK3CG P48736 1/20 0.44
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPK1 P28482 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RECQL P46063 1/20 0.42
MCL1 Q07820 1/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 1/20 0.41
SLC2A1 P11166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740834 0.84 MEN1 (0.47) PIK3CDPIK3CAPIK3CBPIK3CGMAPT
SCHEMBL16748485 0.79 RECQL (0.45) GBA1PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL16550044 0.77 BMI1 (0.49) PIK3CAMAPTKMT2AMEN1L3MBTL1
SCHEMBL15741373 0.77 MAPT (0.48) PIK3CDPIK3CAPIK3CBPIK3CGMAPT
SCHEMBL15742541 0.76 MAPT (0.49) PIK3CDPIK3CAPIK3CBPIK3CGMAPT
SCHEMBL10031977 0.74 SLC2A1 (0.66) MAPTKMT2AMEN1MAPK1CASP1
SCHEMBL16550094 0.71 BMI1 (0.52) PIK3CAMAPTKMT2AMEN1L3MBTL1
SCHEMBL15742378 0.69 MAPT (0.46) MAPTKMT2AMEN1L3MBTL1MAPK1
SCHEMBL34000 0.67 ALDH1A1 (0.55) MAPTKMT2AMEN1MAPK1CASP1
SCHEMBL29355053 0.67 ALDH1A1 (0.55) MAPTKMT2AMEN1MAPK1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B GBA1 4223/4885PIK3CD 2974/4885PIK3CA 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.